Antibody Characterization Report for Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP A2/B1)

This report presents a guide to selecting high-quality commercial antibodies against Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP A2/B1) by immunoblot (Western blot), immunoprecipitation and immunofluorescence, using a knockout based validation approach.

This study was funded in part by the ALS-Reproducible Antibody Platform (ALS-RAP), established as a public-private partnership by three prominent ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.